<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770443</url>
  </required_header>
  <id_info>
    <org_study_id>15-284-MUHC</org_study_id>
    <nct_id>NCT02770443</nct_id>
  </id_info>
  <brief_title>Withdrawal of Medication in Recovered DCM</brief_title>
  <acronym>WrecEF</acronym>
  <official_title>Withdrawal of Beta- Blockers and ACE Inhibitors After Left Ventricular Systolic Function Recovery in Patient With Dilated Cardiomyopathy: A Randomized Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study of medication withdrawal in patients who have recovered LV function in
      Dilated Cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Importance of the study:

      There is a growing population of patients with dilated cardiomyopathy (DCM) who had recovered
      left ventricular (LV) systolic function on medical therapy. Recent studies have shown a
      favorable clinical course in patients with DCM1-4. The heart failure (HF) guidelines states
      that discontinuation of medical therapy in this group of patients may be considered based on
      expert opinion. The safety of withdrawal of medical therapy needs further studies.

      Hypothesis:

      In Patients with dilated cardiomyopathy (DCM) who had recovery of the LV systolic function to
      a normal EF &gt;50%, medical therapy withdrawal is attainable without Clinical deterioration or
      recurrence of LV systolic dysfunction.

      Objective

        1. To study the withdrawal of guideline directed medical therapy, specifically
           beta-blockers and ACE/ARB, in patients with DCM after recovery of LV EF.

        2. Correlate the sustained recovery in LVEF after medication discontinuation with specific
           genetic markers of recovery.

      Method:

      Study design:

      It is a multi-center, non-blinded, randomized Control trial (pilot) comparing withdrawal of
      medical therapy in patients with recovered LVEF (recEF) compared to patients continuing
      medical therapy. Therapeutic changes will occur in a 2:1 randomization at the Royal Victoria
      Hospital, the Montreal General Hospital and the Jewish General Hospital. Patient would be
      recruited from a Heart Function Clinic or the echocardiography lab.

      Procedures:

      Patient Selection:

      Patient selection will be conducted through chart review, ECHO lab, as well as the clinical
      visits. The DPS authorization will be requested.

      Informed consent:

      At time of enrolment the study's objective, procedures as well as the risks and benefits will
      be explained to the patient. A consent form will be provided to the patient. In addition, a
      wallet card and a medication discontinuations chart.

      Randomization:

      Randomization will be conducted in 2:1 fashion, non-blinded, through a sealed envelop
      randomization system.

      Medical therapy withdrawal:

      Medical therapy withdrawal will be conducted in 2 phases.

      Phase 1:

      This phase involves the withdrawal of the beta-blocker. The patient will be followed for
      signs of deterioration for a period of 6 months following the withdrawal.

      Phase 2:

      If there are no signs of deterioration the ACE/ARB inhibitor will be withdrawn as well. The
      patient will be followed up in 6 month for signs of deterioration. All other medical
      therapies other than beta-blocker and ACE inhibitors will continue until successful
      withdrawal of beta-blockers and ACE inhibitor is achieved.

      Beta-blocker discontinuation:

      The initial tapering off will occur over a 2week period. The beta -blocker will be
      discontinued by the end of the 2nd week.

      For example: Metoprolol 100mg bid to Metoprolol 75mg bid for 5days. Followed by Metoprolol
      50mg bid for 4 days, then Metoprolol 25 mg for 3 days and then completely discontinued.

      ACE/ARB discontinuation:

      The discontinuation of ACE/ARB will be similar to the beta-blockers. The doses will be
      tapered over a two-week period.

      A supplementary chart of dose reduction is provided. The doses included are the standard
      medication doses.

      Digoxin, diuretic, spironolactone will be discontinued if both the beta-blocker and ACE-ARB
      discontinuation has been well tolerated or if a clinical indication warrants the
      discontinuation. Up titration of therapies will not be permitted.

      Additional therapy for SBP &gt; 130 or DBP &gt;80mmHg with non-ACE or beta blocker therapy will be
      considered.

      Genotyping: Genetic analysis for DCM causing gene will be sent for the study patients. The
      genotyping is selective, patient will have the option to opt out the genetic analysis if they
      do not prefer having a genotyping done. All samples will be stored in a bio bank to maximum
      of 25 years. Two comparisons will be conducted on the genotyping:

        1. The genetic typing for Patients with improved EF will be compared to the control group
           from the ongoing DCM cohort at the McGill University Health Center.

        2. A second comparison between the patients within the withdrawal cohort. A comparison will
           be made between patients with rebound HF and the patient who did not HF with
           discontinuation of medical therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that remain clinically in NYHA Class I</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients that maintain LVEF &gt; or = 50%</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average BNP level compared to baseline BNP level</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Withdrawal of beta blockers and ACE inhibitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no withdrawal, standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>withdrawal</intervention_name>
    <description>withdrawal of beta blocker and ACE inhibitors</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>withdrawal ACE and beta blockers</other_name>
    <other_name>discontinuation of ACE and beta blockers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of CARE</intervention_name>
    <description>STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient diagnosed with dilated cardiomyopathy (DCM) with an initial HFrEF &lt; 40 % at
             presentation.

          2. DCM with recovered LV function to &gt; or = to 50% documented on 2 ECHO examinations,
             with the most recent ECHO examination within 1 year of enrolment.

          3. Time from initial diagnosis of DCM more or equal to 24 month.

          4. Last hospitalization for decompensated HF &gt; 1year.

        Exclusion criteria:

          1. Ischemic cardiomyopathy

          2. Other structural pathology such as: Hypertrophic cardiomyopathy, Valvular
             cardiomyopathy or congenital heart disease.

          3. Last hospitalization for decompensated HF &lt; 1year ago.

          4. Previous sustained ventricle tachycardia or ventricle fibrillation (VF) arrest.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Giannetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abeer M Bakhsh, MD</last_name>
    <phone>19056164503</phone>
    <email>abeer.bakhsh@mail.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberley V Kotar, Bsc.</last_name>
    <phone>5149341934</phone>
    <phone_ext>35661</phone_ext>
    <email>kimberley.kotar@muhc.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abeer M Bakhsh, MD</last_name>
      <phone>9056164503</phone>
      <email>abeer.bakhsh@mail.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kimberley V Kotar, Bsc</last_name>
      <phone>5149341934</phone>
      <phone_ext>35661</phone_ext>
      <email>kimberley.kotar@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Nadia Giannetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Gupta A, Goyal P, Bahl A. Frequency of recovery and relapse in patients with nonischemic dilated cardiomyopathy on guideline-directed medical therapy. Am J Cardiol. 2014 Sep 15;114(6):883-9. doi: 10.1016/j.amjcard.2014.06.021. Epub 2014 Jul 2.</citation>
    <PMID>25084692</PMID>
  </reference>
  <reference>
    <citation>Moon J, Ko YG, Chung N, Ha JW, Kang SM, Choi EY, Rim SJ. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2009 May;25(5):e147-50.</citation>
    <PMID>19417864</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Guallar E, Blasco-Colmenares E, Butcher B, Norgard S, Nauffal V, Marine JE, Eldadah Z, Dickfeld T, Ellenbogen KA, Tomaselli GF, Cheng A. Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients. J Am Coll Cardiol. 2015 Aug 4;66(5):524-31. doi: 10.1016/j.jacc.2015.05.057.</citation>
    <PMID>26227190</PMID>
  </reference>
  <reference>
    <citation>Blechman I, Arad M, Nussbaum T, Goldenberg I, Freimark D. Predictors and outcome of sustained improvement in left ventricular function in dilated cardiomyopathy. Clin Cardiol. 2014 Nov;37(11):687-92. doi: 10.1002/clc.22331. Epub 2014 Sep 18.</citation>
    <PMID>25236761</PMID>
  </reference>
  <reference>
    <citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5.</citation>
    <PMID>23747642</PMID>
  </reference>
  <reference>
    <citation>Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014 Jun 10;129(23):2380-7. doi: 10.1161/CIRCULATIONAHA.113.006855. Epub 2014 May 5.</citation>
    <PMID>24799515</PMID>
  </reference>
  <reference>
    <citation>Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006 Sep;152(3):509-13.</citation>
    <PMID>16923422</PMID>
  </reference>
  <reference>
    <citation>Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989 Sep;80(3):551-63.</citation>
    <PMID>2548768</PMID>
  </reference>
  <reference>
    <citation>Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J. 1999 Sep;138(3 Pt 1):456-9.</citation>
    <PMID>10467195</PMID>
  </reference>
  <reference>
    <citation>Hopper I, Samuel R, Hayward C, Tonkin A, Krum H. Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis. J Card Fail. 2014 Jul;20(7):522-32. doi: 10.1016/j.cardfail.2014.04.013. Epub 2014 Apr 18. Review.</citation>
    <PMID>24747201</PMID>
  </reference>
  <reference>
    <citation>Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol. 1993 Nov 15;22(6):1557-63.</citation>
    <PMID>8227822</PMID>
  </reference>
  <reference>
    <citation>Nicholls MG, Ikram H, Espiner EA, Maslowski AH, Scandrett MS, Penman T. Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol. 1982 Apr 21;49(6):1497-501.</citation>
    <PMID>6803564</PMID>
  </reference>
  <reference>
    <citation>Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992 Aug;86(2):431-8.</citation>
    <PMID>1638712</PMID>
  </reference>
  <reference>
    <citation>Shammas NW, Harris ML, McKinney D, Hauber WJ. Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers. Clin Cardiol. 2001 Dec;24(12):786-7.</citation>
    <PMID>11768743</PMID>
  </reference>
  <reference>
    <citation>Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003 Dec 3;42(11):1944-51.</citation>
    <PMID>14662257</PMID>
  </reference>
  <reference>
    <citation>Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, Jurado A, Salas C, Gomez-Diaz I, Padron-Barthe L, Grillo JJ, Vilches C, Segovia J, Pascual-Figal D, Lara-Pezzi E, Monserrat L, Alonso-Pulpon L, Garcia-Pavia P; Inherited Cardiac Diseases Program of the Spanish Cardiovascular Research Network (Red Investigaci√≥n Cardiovascular). Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant. 2016 May;35(5):625-35. doi: 10.1016/j.healun.2015.12.014. Epub 2016 Jan 6.</citation>
    <PMID>26899768</PMID>
  </reference>
  <reference>
    <citation>Sheppard R, Hsich E, Damp J, Elkayam U, Kealey A, Ramani G, Zucker M, Alexis JD, Horne BD, Hanley-Yanez K, Pisarcik J, Halder I, Fett JD, McNamara DM; IPAC Investigators. GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study. Circ Heart Fail. 2016 Mar;9(3):e002683. doi: 10.1161/CIRCHEARTFAILURE.115.002683.</citation>
    <PMID>26915373</PMID>
  </reference>
  <reference>
    <citation>Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J 3rd, McNamara DM, Seidman CE, Seidman JG, Arany Z; IMAC-2 and IPAC Investigators. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016 Jan 21;374(3):233-41. doi: 10.1056/NEJMoa1505517. Epub 2016 Jan 6.</citation>
    <PMID>26735901</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Nadia Giannetti</investigator_full_name>
    <investigator_title>Chief, Division of Cardiology, Director of Heart Function Clinic</investigator_title>
  </responsible_party>
  <keyword>Recovered LVEF</keyword>
  <keyword>DCM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

